Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system


Tuesday, 10 Dec 2013 08:31am EST 

Zogenix Inc:Says the US FDA has approved the supplemental NDA for a four mg dose of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.Says SUMAVEL DosePro has been available in a six mg dose for the treatment of acute migraine and cluster headache.Says the four mg dose of SUMAVEL DosePro can be used to help migraine sufferers who require management of side effects.Says the four mg dose of SUMAVEL DosePro is expected to be available about June 2014.Says SUMAVEL DosePro is the first and only needle-free delivery system for subcutaneous sumatriptan for the treatment of acute migraine and cluster headache.Says Clinical data has shown that the current six mg dose of SUMAVEL DosePro can provide migraine pain relief within 10 minutes for some patients (16 pct of patients versus 4pct for placebo). 

Company Quote

1.37
0.02 +1.48%
2 Sep 2014